San Diego’s Biocept Inc. has partnered with a university in Oregon under an arrangement will allow the school’s cancer center to offer Biocept’s testing services exclusively throughout the state of Oregon.

The agreement is with Oregon Health & Sciences University on behalf of OHSU Knight Cancer Institute (collectively known as OHSU).

Biocept is a local molecular diagnostics company developing liquid biopsies to improve the detection and treatment of cancer. The company offers a blood-based method that detects and monitors biomarkers, which can lead to physicians making better informed treatment decisions based on genetic information.

OHSU will commercially offer Biocept’s tests, and will also use the tests in-house, acting as a second lab for Biocept’s research and testing activities. Together, Biocept and OHSU plan to develop new liquid biopsy tests, according to a Biocept news release.

"Liquid biopsy offers several advantages including the ability to obtain molecular information from a patient's cancer rapidly and non-invasively,” Christopher Corless, executive director an dchief medical officer of OHSU’s Knight Diagnostic Laboratories, said in a statement. “The high sensitivity and low cost potential of Biocept's Target Selector platform was attractive to us, and we look forward to working with the company to develop additional assays, multiplexed panels, and applications of this technology to improve patient care."